OBJECTIVES: To determine whether benzodiazepine use in older women increased the risk of decline in physical function. DESIGN: A four-year prospective cohort study. SETTING: The communities of Iowa and Washington counties, Iowa. PARTICIPANTS: Eight hundred eighty-five women aged 70 and older who had completed physical performance tests in 1988 and 1992. MEASUREMENTS: Benzodiazepine use was determined during in-home interviews and classified by dose, duration, indication for use, and half-life. Physical performance tests included an assessment of standing balance, walking speed (8-foot distance), and repeated chair raises. RESULTS: Ninety (10.2%) reported benzodiazepine use at baseline. After adjustment for baseline physical performance score and potential confounders, benzodiazepine use was associated with a greater decline in physical performance over 4 years than nonuse (beta=-1.16; standard error (SE)=0.25; P<.001). The use of higher-than-recommended dose was related to decline (beta=-2.26; SE=0.47; P<.001), and use of lower doses was not (beta=-0.53; SE=0.46; P=.246). Long-term use (>or=3 years) was related to decline (beta=-1.65; SE=0.34; P<.001), whereas recent and past use were not. Similar results were obtained when restricting the sample to those without disability at baseline. CONCLUSION: This study provides evidence that older women who used benzodiazepines were at risk for decline in physical performance. Subgroup analyses indicated that risk was greater with use of higher-than-recommended doses or for long duration (>or=3 years). These findings highlight the importance of using benzodiazepines at the lowest effective dose for a limited duration in older women.
OBJECTIVES: To determine whether benzodiazepine use in older women increased the risk of decline in physical function. DESIGN: A four-year prospective cohort study. SETTING: The communities of Iowa and Washington counties, Iowa. PARTICIPANTS: Eight hundred eighty-five women aged 70 and older who had completed physical performance tests in 1988 and 1992. MEASUREMENTS: Benzodiazepine use was determined during in-home interviews and classified by dose, duration, indication for use, and half-life. Physical performance tests included an assessment of standing balance, walking speed (8-foot distance), and repeated chair raises. RESULTS: Ninety (10.2%) reported benzodiazepine use at baseline. After adjustment for baseline physical performance score and potential confounders, benzodiazepine use was associated with a greater decline in physical performance over 4 years than nonuse (beta=-1.16; standard error (SE)=0.25; P<.001). The use of higher-than-recommended dose was related to decline (beta=-2.26; SE=0.47; P<.001), and use of lower doses was not (beta=-0.53; SE=0.46; P=.246). Long-term use (>or=3 years) was related to decline (beta=-1.65; SE=0.34; P<.001), whereas recent and past use were not. Similar results were obtained when restricting the sample to those without disability at baseline. CONCLUSION: This study provides evidence that older women who used benzodiazepines were at risk for decline in physical performance. Subgroup analyses indicated that risk was greater with use of higher-than-recommended doses or for long duration (>or=3 years). These findings highlight the importance of using benzodiazepines at the lowest effective dose for a limited duration in older women.
Authors: Sarah N Hilmer; Donald E Mager; Eleanor M Simonsick; Shari M Ling; B Gwen Windham; Tamara B Harris; Ronald I Shorr; Douglas C Bauer; Darrell R Abernethy Journal: Am J Med Date: 2009-12 Impact factor: 4.965
Authors: Shelly L Gray; Andrea Z LaCroix; Joseph T Hanlon; Brenda W J H Penninx; David K Blough; Suzanne G Leveille; Margaret B Artz; Jack M Guralnik; Dave M Buchner Journal: J Am Geriatr Soc Date: 2006-02 Impact factor: 5.562
Authors: Robert M Boudreau; Joseph T Hanlon; Yazan F Roumani; Stephanie A Studenski; Christine M Ruby; Rollin M Wright; Sarah N Hilmer; Ronald I Shorr; Douglas C Bauer; Eleanor M Simonsick; Anne B Newman Journal: Pharmacoepidemiol Drug Saf Date: 2009-10 Impact factor: 2.890
Authors: Megan E Petrov; Patricia Sawyer; Richard Kennedy; Laurence A Bradley; Richard M Allman Journal: Arch Gerontol Geriatr Date: 2014-05-06 Impact factor: 3.250
Authors: Constance H Fung; Jennifer L Martin; Karen Josephson; Lavinia Fiorentino; Joseph M Dzierzewski; Stella Jouldjian; Yeonsu Song; Juan Carlos Rodriguez Tapia; Michael N Mitchell; Cathy A Alessi Journal: Clin Gerontol Date: 2017-09-29 Impact factor: 2.619